
Declining Birthrates Are Breaking The Economy. Can We Fix It In Time?
Fertility rates are in free fall, with no clear solutions having emerged as of yet. A handful of ... More CEOs are up for the challenged.
Look closely and you'll notice it.
The subtle pull of gravity after a long sprint towards the edge, the tiny tremor in our economic step as it fails to find solid ground underneath, the mounting silence where there used to be the noise of new life.
We are on what animators call Coyote Time: the few fleeting seconds between sprinting off the cliff and looking down, when gravity hasn't quite caught up but the fall is inevitable.
The global economy, led by the aging West and now followed by much of East Asia, has sprinted confidently into the abyss of demographic collapse like Wile E. Coyote in pursuit of our very own roadrunner that Emile Durkheim presciently described a century ago as the 'malady of infinite aspiration.'
Birthrates are in freefall, and while we're saying the words out loud more often, we've yet to process what this means for our societies, our businesses, or the very survival of the economic model our current form of civilization depends on.
Toby Ord and others in the longtermist camp have been sounding the alarm for years.
In The Precipice, he outlines a spectrum of existential risks facing humanity, from engineered pandemics to unaligned AI, but undergirding many of these is the quieter collapse of our demographic engine. If there are no people, there is no future to protect.
While longtermism has found its home in academic circles and a handful of venture capital firms thinking centuries ahead, the population crisis hasn't yet pierced the mainstream with the same urgency.
But Ord's insight remains prescient: if humanity fails to invest in the conditions that allow it to continue, reproduction among them, then even the most sophisticated civilisations will eventually be reduced to footnotes in someone else's survival story.
This is the abyss we are levitating over, still in chase of greater affluence regardless of how sternly Galbraith and others have warned us to still our all-consuming hearts.
The demographic cliff will end us, unless we act quickly.
As Cole Napper, VP of Research at Lightcast puts it, 'You can't have an economy without people, and right now, we're losing both.'
According to Lightcast's latest report, the U.S. population is growing four times faster than its labor force. That gap is barely held together by immigration, and increasingly, by duct tape. The prime-age male labor force is eroding particularly fast, lost to disillusionment, systemic failures, substance abuse, and in many cases, sheer hopelessness.
And it's not just an American problem. Japan is decades into its population contraction. China's demographic decline has officially begun. Even the Nordic countries, long viewed as social policy success stories, are struggling to reverse the trend. The demographic future isn't looming. It's here, even if our earlier momentum still keeps us going.
'This isn't hyperbole,' Napper adds.
'It's not that we're all going to die. But your needs are not going to be met in the ways they are today. The expectations we've built into every institution, every business model—they just won't hold any more.'
We have not faced an existential threat with such clear implications for our economy before.
There's no precedent for what happens when an entire economic system built on constant growth finds itself with fewer hands to work, fewer children to teach, fewer buyers for the homes, and fewer taxpayers to sustain the state.
Faced with a future as bleak as this, it's only natural to ask what is driving it, and what could we do about it?
There's no singular villain here.
The decline in birthrates isn't the result of one policy or one cultural shift; it's a slow-motion trainwreck caused by everything, everywhere, all at once.
'We've tried paying people,' Napper says. 'But money doesn't fix this. It's not just an economic decision or a transaction the government or employer can influence with just money. It's personal. People are making very deliberate choices about the kind of life they want, and many are deciding not to replicate the one they've lived.'
In part, we've overoptimized for affluence.
Modern life is a relentless treadmill of degrees, performance reviews, debt, and the promise that things will get better if you just stick it out.
But what if better never comes? What if the very structure of our success makes having children feel like a selfish, impossible luxury?
And yet, some make it all happen.
Dr. Dara Spearman had her twins during residency, a time most physicians would call the peak of professional chaos.
'It was insane,' she says, not with regret, but clarity. 'I was seeing patients, studying, and barely sleeping. There were no policies that accounted for women like me. I just had to make it work.'
She did more than make it work.
Spearman went on to have another child, build a thriving dermatology practice, and become a role model for the kind of life that dares to exist because of work, not in spite of it.
'I didn't have the luxury of waiting for things to be perfect,' she reflects. 'If I had waited until my career said I was 'ready,' I'd probably still be waiting, and my life wouldn't be half of what it is today. '
What sets those like Spearman apart is not that she balanced motherhood and medicine, it's that she refused to treat one as the cost of the other. 'Women are often asked to delay, to sacrifice, to optimize every aspect of life before they consider becoming a parent. But that logic folds in on itself. You wake up one day and realize the thing you were waiting for might never come.'
Now, as the owner of Radiant Dermatology Associates she's doing things differently.
Spearman intentionally built her clinic around flexibility and sustainability, for her patients, yes, but also for her staff. 'I want people who work with me to feel like they can live a life, take time with their families, show up at school plays, go on vacation without guilt. Otherwise, what are we even doing this for?'
She's right.
In the U.S., puppies legally get more time with their mothers before they can be separated than most newborns. In a world where everything demands 110%, parenting often feels like subtraction from a life you've worked hard to build.
And for many, it's not just a question of whether they want to add kids to that equation, it's whether they can afford the tradeoffs.
In a sense, declining fertility rates are only the tip of the iceberg where rising maternal health risks, lack of access to basic reproductive education are what drives the trends underneath.
As usual, where institutions lag, entrepreneurs leap, with many having found productive niches in addressing the underpinnings of the demographic cliff.
It's no surprise, then, that some of the most compelling responses to our demographic dilemma are coming from founders who saw a problem not because they studied it, but because they lived it.
Ayla Barmmer's company, FullWell, was born out of personal frustration and professional observation.
A reproductive health expert and maternal nutritionist by training, she was struck by how disconnected the journey to pregnancy still is from what we know about health and biology.
'We treat conception like a light switch,' she says.
'You flip it on when you're ready and expect everything to work. But that's not how the body works. There's a whole ecosystem that has to be nurtured long before someone takes a pregnancy test.'
Her own path to pregnancy revealed something sobering: even well-informed, resourced women were navigating it blindly.
'I was shocked by how many gaps there still are in basic education. Most OBs don't talk about preconception health. And men? Men don't even get mentioned. But they're half the equation by design.'
Barmmer and her team is building an evidence-based reproductive health company that flips the model by tackling the cohesive whole of the experience instead of offering a point solution.
'We've got apps for hydration and step-counting,' she says, 'but nothing that helps you prepare for the most biologically complex, emotionally taxing, socially transformative experience of your life? That's absurd. We need a new standard where preparing for pregnancy is just as normalized as preparing for a marathon.'
Where Barmmer tackles the front end of the journey, Shaker Rawan is focused on what comes after: the parenting spiral where joy, exhaustion, and panic blur together in real time.
As co-founder of Woddle, Rawan wants to rebuild the village that modern parenthood has lost. 'We expect parents today to carry more weight than any generation before them, with less help, more judgment, and higher stakes,' he says. 'It's a cruel setup that can turn many off from the experience just by witnessing others go through it.'
He's not exaggerating.
In many developed countries, the average number of caregivers per child has dropped drastically in just two generations. What once was a multigenerational web of care is now two exhausted adults, often in nuclear households far from extended family, juggling careers and survival.
'People look at new parents and they don't see inspiration, they see burnout,' Rawan adds.
'They see the stress, the anxiety, sometimes even tragedy. And they think, 'Why would I sign up for that?''
Woddle offers a digital scaffolding: evidence-based resources, mental health support, and community features that connect parents in real time.
But Rawan is adamant that solving this will need more than just high-tech products.
'We can't solve this with gadgets. What people need is permission to not be perfect. They need community, emotional safety, and to be told that it's okay to ask for help. Because the alternative is watching future generations opt out before they even opt in.'
He's also acutely aware of the modern cognitive burden. 'Our parents raised us with Dr. Spock and a pediatrician. Today's parents are drowning in TikTok experts, Reddit forums, and ten thousand parenting philosophies. They're expected to have encyclopedic knowledge and zero margin for error.'
Which brings us to Omri Stivi, who's trying to turn the flood of chaotic information into a navigable system.
His new company, EraBorn, aims to do for fertility and parenting what GPS did for navigation: offer clear, contextual, step-by-step guidance through an overwhelming journey to parenthood . 'Right now, we raise kids with vibes and Google searches,' he says. 'We trust data to decide our ad spend, our workouts, our business models, but not our parenting or fertility journeys?'
Stivi is building a platform draws on clinical research, pediatric consensus, machine learning, large language models and behavioral science to help parents make informed decisions. Instead of replacing parental instinct, he strives to support it.
'We've heard heartbreaking cases of individuals and couples who arrived at a clinic only to be told it was too late-, they would never become parents,' Omri shares. 'We strive to prevent that. Era provides smart, informed navigation and timely decision-making, along with personalized referrals to relevant professionals and resources, before and during pregnancy, so no one misses their window of opportunity.'
'We're not here to tell parents what to do,' Stivi clarifies. 'I'm here to give them the same tools and transparency they expect everywhere else in life. If you can benchmark a company, you should be able to benchmark a fertility protocol, pregnancy plan or feeding schedule.'
He also challenges the cultural assumption that parenting is just 'natural.' 'It's the most complex thing we do as humans. It's also the least supported, least structured, and somehow the least personalized and professionalized. That has to change.'
Like Rawan, he sees this lack of structure as a deterrent for would-be parents. 'If you saw what your friends went through, and all you have is guesswork ahead of you, why would you do it?'
All three of these founders circle the same core insight: parenting doesn't need to be easy. But it should be less opaque, less isolating, and less punishing.
'We built a society that treats children like private decisions instead of public investments,' Barmmer says. 'And now we're surprised people are opting out.'
Whether through better preconception health, richer support networks, or clearer information systems, each of these entrepreneurs is laying a stone on the path back from the cliff. Not because they have all the answers, but because they refuse to accept the current default.
As Rawan puts it: 'We talk about population collapse like it's inevitable. It's not. But we have to make having kids make sense again. Not as sacrifice, but as fulfillment. Not as martyrdom, but as meaning.'
If you're one of those who believes the birthrate panic is overblown, you're right.
Humanity is not going extinct.
Within every country, every culture, there are subgroups having 2.1 or more children per woman. In the U.S., that might be Orthodox Jews or certain Mormon communities. In the Middle East, the Taliban is outpacing the liberal West demographically. In Africa, the birthrate remains high, even if the economies haven't yet caught up.
As Napper puts it: 'All of this is individual decisions, playing out at scale. And it's not distributed evenly. Some groups are growing. Others are vanishing. The future will belong to the ones who choose to build it.'
What's changing is the composition of those who will inherit the Earth.
And maybe that's the part that should give us pause. The future belongs not to the smartest or the richest, but to those who are willing to invest in it through children, communities, and sacrifice.
Demographics do not have to be destiny.
What we do now, how we support families, how we shift work, how we make room for joy and rest and generational care, will determine what kind of civilization makes it through this bottleneck.
The abyss is real. But so is the ledge on the other side.
The question is, will we build a bridge? Or wait until we run out of Coyote Time and fall?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fast Company
an hour ago
- Fast Company
Frontline workers feel so disconnected, nearly half don't know who their CEO is
Frontline workers, those non-desk workers who do some of the most demanding jobs, don't always feel connected to the company they work for. In fact, many say their team has an entirely distinct culture of its own and that communication with their company leaves a lot to be desired. According to a new global survey of 7,550 workers from Workvivo by Zoom, while frontline workers make up 80% of the global workforce, many say they don't get the recognition they deserve. Frontline workers know how essential their duties are. In fact, 49% say they feel their impact is greater than that of their office colleagues. They just don't feel recognized for it. Likewise, 40% say their company doesn't care about them as a person. A separate corporate culture Overall, according to the new findings, frontline workers feel largely disconnected to in-office culture. A staggering 87% said that their company's culture doesn't apply to frontline workers. Half of frontline workers feel that their team has its own specific culture that doesn't mirror that of the company's overall vibe. And a huge chunk of frontline workers feel so disconnected from their company they don't even know who runs it. Nearly half (46%) said they don't know who their CEO is. One glaring reason why frontline workers feel so disconnected from in-office culture seems to be a lack of communication. According to the report, 38% say they have feedback for higher-ups, but no way of communicating it. Forty-two percent say that the leaders at their company aren't good at reaching out to their team. Forty-eight percent say their company's communication feels irrelevant to frontline workers. Connecting with frontline staff Another recent report by Staffbase similarly found a communication disconnect among frontline workers. The research found only 9% of non-desk workers were very satisfied with internal communication. And it seems to be an issue that leads to overall workplace unhappiness and drives turnover. Sixty-three percent of employees who are considering leaving their position say poor internal communication is a factor. Meanwhile, most frontline workers aren't checked out. In fact, they want more communication. The latest report found that 69% of frontline workers want to better understand their company's decisions. Essentially, those on the frontlines want clear communication, to feel connected, and to be heard by the company they represent. 'Our research shows that frontline employees feel disconnected not because they care less, but because they are engaged less,' said Gideon Pridor, CMO & chief storyteller at Workvivo, by Zoom in a press release. 'To close this critical gap, organizations need to recognize frontline contributions in real time, communicate in ways that are relevant and accessible, and provide clear and visible paths for growth.'


Forbes
2 hours ago
- Forbes
Medtronic Announces Intent To Spin Diabetes Business
(Photo Illustration by) Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic's portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value. Post spin-off, Medtronic (RemainCo) will continue to operate as a diversified MedTech innovator, concentrating on its core franchises in cardiovascular, neuroscience, surgical, and medical-surgical technologies. Further, the company aims to accelerate growth through innovation in areas like pulsed field ablation, renal denervation, soft tissue robotics, and neuromodulation. Meanwhile, the New Diabetes Company (NewCo) will be offering a complete ecosystem for intensive insulin management, including insulin pumps, continuous glucose monitoring (CGM), and digital health solutions. The separation is expected to be completed within 18 months, primarily through a capital markets transaction, with a preferred path of an initial public offering (IPO) followed by a split-off. The transaction is expected to be tax-free to Medtronic shareholders for US federal income tax purposes. The separation will include the Diabetes business employees, product portfolio, pipeline, intellectual property, strategic partnerships, and global manufacturing facilities. Medtronic Price Performance Spin-Off Details and Top 5 Shareholders The transaction is anticipated to be accretive to Medtronic's gross and operating margins, and earnings per share, while enabling the NewCo to pursue focused innovation and growth strategies tailored to the diabetes market. It is also expected to provide the ability to retire Medtronic shares outstanding without reducing cash, resulting in EPS accretion and a reduction in the dividend liability for Medtronic, enabling increased growth-accretive investment. Medtronic expects its dividend per share to remain unchanged pre- and post-transaction with no change to its dividend policy. The spin-off is subject to customary regulatory approvals, board consent, and market conditions. Que Dallara, current EVP and president of Medtronic Diabetes, will become CEO of New Diabetes Company. Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as financial advisors to Medtronic in its review of strategic alternatives for the New Diabetes Company. Key Data Deal Rationale Medtronic, a global leader in MedTech, is planning to spin off its Diabetes business into a standalone entity, as part of a strategic move to sharpen its focus on higher-margin, faster-growing segments such as Cardiovascular, Neuroscience, and Medical-Surgical, which together account for over 90.0% of its total revenues. The Diabetes segment, contributing approximately $2.5 billion in FY25 (about 8.0% of Medtronic's total $32.4 billion in revenue), has consistently underperformed over the past five years, with a revenue CAGR of just ~1.4% compared to Medtronic's overall ~2.9% CAGR. Segment profitability has also lagged: while Medtronic's overall operating margin stands at ~15.9%, the diabetes unit has been a drag, reportedly generating operating losses in the low teens in its core U.S. market. In FY19, the segment posted a strong operating margin of 30.9% but steadily declined to 24.8–24.9% through FY21 and FY22, before dropping significantly to 15.8% in FY25. Multiple headwinds contributed to this underperformance, including FDA regulatory setbacks, such as the 2021 warning letter and delayed approval of the MiniMed 780G insulin pump and Guardian 4 sensor, alongside intensifying competition from more agile players like Dexcom, Abbott, Tandem, and Insulet. These rivals outpaced Medtronic with faster innovation in continuous glucose monitoring (CGM) and closed loop insulin delivery systems. Furthermore, the rising adoption of GLP-1 receptor agonists (e.g., Ozempic, Mounjaro) is shifting treatment paradigms, particularly for Type 2 diabetes, reducing demand for insulin pumps. Despite a recent rebound, with the diabetes segment growing ~10.7% YoY in FY25 and six consecutive quarters of double-digit growth, the improvement is seen as insufficient to offset the structural challenges and lower returns relative to the rest of Medtronic's portfolio. By spinning off the diabetes business, Medtronic aims to lift its gross margin by approximately 50 basis points, adjusted operating margins by approximately 100 basis points, and be immediately accretive to adjusted EPS. As per management, following this separation, Medtronic is expected to increase focus on innovation-driven growth and category leadership for healthcare systems and physician customers. The company will have enhanced benefit from its scale and strategic commercial, manufacturing, and technology synergies. On the other hand, this separation is expected to enable more focused investment into New Diabetes Company's pipeline, as well as manufacturing scale and automation, positioning the company for success in Automated Insulin Delivery and Smart MDI, while driving margin expansion over time. At the same time, it will create an independent, scaled leader in Diabetes, focused on accelerating innovation and differentiated as the only company to commercialize a complete ecosystem to address intensive insulin management. The separation is also expected to unlock value for Medtronic and its shareholders, as it creates a New Diabetes Company shareholder base more aligned with its financial profile. Medtronic plc is a global healthcare technology leader that designs and manufactures medical devices and therapies to treat a wide range of chronic and acute health conditions. The company operates in over 150 countries and focuses on improving patient outcomes through innovation in areas such as AI, robotics, and data-driven care. Medtronic's operations are structured into four major segments, each addressing a distinct area of healthcare technology. The Cardiovascular segment includes heart rhythm devices, heart valves, and vascular therapies for treating cardiac and circulatory conditions. The Neuroscience segment offers spinal implants, stroke treatment devices, and neuromodulation systems for managing neurological and musculoskeletal disorders. The Medical Surgical segment provides surgical tools, robotic-assisted systems, and patient monitoring technologies, while the Diabetes segment delivers insulin pumps, continuous glucose monitoring systems, and smart insulin pens to help manage diabetes effectively. Cardiovascular: The Cardiovascular segment is dedicated to treating heart and vascular diseases through advanced medical technologies. It includes three subsegments: Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular. This segment offers pacemakers, implantable defibrillators, heart valves, ablation systems, and vascular stents. In FY25, it generated $12.4 billion in revenue (37.2% of total revenue), growing 5.5%. Medtronic continues to lead in innovations like leadless pacing and pulsed field ablation, addressing both chronic and acute cardiac conditions globally. • Cardiac Rhythm & Heart Failure (CRHF): CRHF focuses on devices tha manage abnormal heart rhythms and heart failure. It includes pacemakers like the Micra leadless system, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and insertable cardiac monitors. The segment also includes cardiac ablation systems and remote monitoring services.• Structural Heart & Aortic (SHA): SHA provides solutions for heart valve disorders and aortic diseases. It includes transcatheter aortic valve replacement (TAVR) systems like Evolut FX, surgical heart valves, perfusion systems, and endovascular stent grafts. These devices are used in both minimally invasive and open-heart procedures.• Coronary & Peripheral Vascular (CPV): CPV delivers therapies for coronary artery disease and peripheral vascular conditions. It includes druge luting stents (e.g., Onyx Frontier), angioplasty balloons, renal denervation systems (e.g., Symplicity Spyral), and venous disease treatments like VenaSeal. Neuroscience: The Neuroscience segment addresses neurological and musculoskeletal disorders through surgical and therapeutic technologies. It includes Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation. This segment integrates robotics, AI, and navigation systems to improve surgical precision and patient outcomes. In FY25, it generated $9.8 billion in revenue (29.4% of total revenue), growing 4.7%. Medtronic's innovations in spine surgery, stroke treatment, and neuromodulation continue to drive global adoption. • Cranial & Spinal Technologies (CST): CST develops surgical solutions for spine and cranial procedures. It includes implants, biologics, and enabling technologies like Mazor robotics, StealthStation navigation, and UNiD AI-driven planning. These tools help surgeons perform complex procedures with greater accuracy.• Specialty Therapies: This subsegment includes neurovascular, ENT (ear, nose, and throat), and pelvic health therapies. It offers stroke treatment devices like Solitaire and Pipeline, sinus implants like Propel, and bladder control systems like InterStim. These minimally invasive solutions address critical conditions and improve quality of life.• Neuromodulation: Neuromodulation provides implantable systems for managing chronic pain, movement disorders, and epilepsy. It includes spinal cord stimulators (e.g., Intellis, Inceptiv), deep brain stimulation (e.g., Percept), and drug infusion pumps (e.g., SynchroMed). These technologies personalize therapy using real-time Surgical: The Medical Surgical segment supports hospitals and surgical centers with advanced tools and monitoring systems. It includes Surgical & Endoscopy and Acute Care and Acute Care & Monitoring sub-segments. This segment offers robotic-assisted surgery, AI-powered endoscopy, and patient monitoring solutions. In FY25, it generated $8.4 billion in revenue (25.1% of total revenue), a decrease of 0.1%.• Surgical & Endoscopy (SE): SE provides advanced surgical instruments and digital surgery platforms. It includes stapling systems (e.g., Tri-Staple), vessel sealers (e.g., LigaSure), robotic-assisted surgery (Hugo RAS), and AI-powered endoscopy (GI Genius). These tools enhance surgical precision and efficiency.• Acute Care & Monitoring (ACM): ACM focuses on patient monitoring and respiratory care. It includes pulse oximetry (Nellcor), capnography (Microstream), airway management (Shiley), and brain monitoring (BIS). These solutions help clinicians manage critical care and reduce complications. Diabetes: The Diabetes segment is dedicated to managing Type 1 and Type 2 diabetes through smart, connected technologies. It includes insulin pumps (e.g., MiniMed 780G), continuous glucose monitoring (CGM) systems (e.g., Guardian), and smart insulin pens (e.g., InPen). In FY25, the segment generated $2.8 billion in revenue (8.2% of total revenue), growing 10.7%. Medtronic's diabetes solutions aim to automate insulin delivery and simplify disease management. The MiniMed 780G system features SmartGuard technology, which adjusts insulin every 5 minutes and includes a meal detection algorithm. The Guardian CGM system provides real-time glucose data, while the InPen smart pen integrates with CGM to guide dosing. Medtronic is focused on expanding access to automated insulin delivery systems and competing with pharmaceutical alternatives by emphasizing long-term glycemic control and patient empowerment. Revenue Trend and Adjusted Operating Profit vs. Margin Trend 4Q25 Total revenue grew by 3.9% YoY to $8.9 billion (+1.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments. International markets and new product launches made significant contributions to the growth. Cardiovascular segment revenue grew 6.6% YoY to $3.3 billion, driven by a 9.2% YoY increase in the Cardiac Rhythm & Heart Failure segment, a 6.9% YoY increase from the Structural Heart & Aortic segment, offset by a 0.2% YoY decline in the Coronary & Peripheral Vascular segment. Neuroscience segment revenue increased 2.9% YoY to $2.6 billion, driven by a 4.0% YoY increase in the Cranial & Spinal Technologies segment, a 9.5% YoY increase in the Neuromodulation segment, offset by a 2.4% YoY decline in the Specialty Therapies segment. Medical Surgical segment revenue improved 0.6% YoY to $2.2 billion, driven by a 0.2% YoY increase in the Surgical & Endoscopy segment, and a 6.3% YoY increase in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.3% YoY to $728.0 million, driven by strong US adoption of the MiniMed 780G system with high Continuous Glucose Monitor attachment and international pump upgrades to the Simplera Sync sensor. Adjusted operating income grew 7.6% YoY to $2.5 billion (-0.3% vs. consensus), and the corresponding margin improved ~94 bps to 27.8%, driven by strong revenue growth across key portfolios and disciplined expense management. Operating leverage from higher sales and lower SG&A as a percentage of revenue also contributed to margin expansion. Adjusted net income increased 7.8% YoY to $2.1 billion (+2.7% vs. consensus), and the corresponding margin grew ~84 bps to 23.3%. Adjusted diluted earnings per share came in at $1.62 (4Q24: $1.46), beating the consensus estimates by 2.7%. 4Q25 Revenue FY25 Total revenue grew by 3.6% to $33.5 billion (+0.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments, with notable growth in Cardiac Ablation. Continued innovation, international expansion, and new product approvals also supported overall growth. Cardiovascular segment revenue grew 5.5% to $12.5 billion, driven by a 6.6% increase in the Cardiac Rhythm & Heart Failure segment, a 2.3% increase from the Coronary & Peripheral Vascular segment, offset by a 0.1% decline in the Structural Heart & Aortic segment. Neuroscience segment revenue increased 4.7% to $9.9 billion, driven by a 4.6% increase in the Cranial & Spinal Technologies segment, a 10.7% increase in the Specialty Therapies segment, and a 1.2% growth in the Neuromodulation segment. Medical Surgical segment revenue declined 01% to $8.4 billion, due to 0.2% decline in the Surgical & Endoscopy segment, and offset by 0.1% growth in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.7% to $2.7 billion. Adjusted operating income grew 4.5% to $8.6 billion (in line with consensus), and the corresponding margin improved ~23 bps to 25.8%, driven by strong revenue growth and lower SG&A expenses. Adjusted net income increased 2.3% to $7.1 billion (+0.8% vs. consensus), while the corresponding margin contracted ~27 bps to 21.1%. Adjusted diluted earnings per share came in at $5.49 (FY24: $5.20), beating the consensus estimates by 0.6%. FY25 Revenue Company DescriptionMedtronic plc (Parent) Medtronic plc, headquartered in Galway, Ireland, is the world's leading healthcare technology company, committed to alleviating pain, restoring health, and extending life. With over 95,000 employees across more than 150 countries, Medtronic delivers innovative solutions for more than 70 health conditions. The company operates through four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. These segments encompass a wide range of technologies, including cardiac rhythm devices, spinal and brain therapies, surgical tools, and insulin delivery systems. New Diabetes Company (Spin-Off) The New Diabetes Company will emerge as a leading global direct-to-consumer diabetes care provider, uniquely offering a comprehensive ecosystem for intensive insulin management. With a portfolio that includes insulin pumps, continuous glucose monitoring (CGM) systems, and digital health solutions, it empowers individuals to manage diabetes with greater ease and freedom. Backed by a dedicated team of over 8,000 employees and a robust global infrastructure, the company is poised to accelerate innovation in Automated Insulin Delivery and Smart Multiple Daily Injections (MDI). Organization Structure


Bloomberg
2 hours ago
- Bloomberg
A Disturbing Reversal in the Real Price of Eggs
Progress going backwards Hello and welcome to the newsletter, a grab bag of daily content from the Odd Lots universe. Sometimes it's us, Joe Weisenthal and Tracy Alloway, bringing you our thoughts on the most recent developments in markets, finance and the economy. And sometimes it's contributions from our network of expert guests and sources. Whatever it is, we promise it will always be interesting. If you like chatting with us, check out the Odd Lots Discord, where you can hang out and talk with us and with other listeners 24/7.